Found: 6
Select item for more details and to access through your institution.
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S521, doi. 10.1093/cid/civ518
- By:
- Publication type:
- Article
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S507, doi. 10.1093/cid/civ626
- By:
- Publication type:
- Article
Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S514, doi. 10.1093/cid/civ672
- By:
- Publication type:
- Article
Changes in immunological parameters by ageing in rural healthy Indian adults and their associations with sex and lifestyle.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-19227-z
- By:
- Publication type:
- Article
Correction: Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
- Published in:
- PLoS ONE, 2015, v. 10, n. 9, p. 1, doi. 10.1371/journal.pone.0137816
- By:
- Publication type:
- Article
Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
- Published in:
- PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0117820
- By:
- Publication type:
- Article